Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201211017 Principal Investigator: Linette, Gerald
Title: A multicentre, open label, randomized Phase II trial of the MEK inhibitor pimasertib or dacarbazine in previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cutaneous melanoma
Phase: II Disease Site: Melanoma, Skin
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
In this study we will compare Pimasertib to Dacarbazine. The primary research study goal is to compare the length of time, during and after treatment, in which patients can live without their disease getting worse. Additional purposes of the study are to find out about the side effects of Pimasertib, to evaluate and compare quality of life and to evaluate further anti-cancer effects.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)